Clinical Trials Directory

Trials / Completed

CompletedNCT05945108

Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDER

Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDER: Multicenter Retrospective Study (Real World Evidence - RWE)

Status
Completed
Phase
Study type
Observational
Enrollment
400 (actual)
Sponsor
AstraZeneca · Industry
Sex
All
Age
18 Years – 100 Years
Healthy volunteers
Not accepted

Summary

A national, multicenter, non-randomized, retrospective, observational study (Real-World Evidence-RWE) aimed at analyzing clinical presentation profiles and demographic characteristics of patients with early urothelial bladder cancer (high-risk non-muscle invasive and localized muscle-invasive) treated with standard therapies in national cancer treatment reference centers within the last 6 years (between 2017 and 2022).

Detailed description

Urothelial carcinoma has several histological types, extensive genetic diversity and a wide array of risk factors related to disease development. Moreover, the treatment effectiveness may be widely impacted by factors such as age, previous comorbidities, socio-economic factors, late diagnosis and access to treatment. In the last decade, the treatment profile has evolved worldwide with the incorporation of new technologies, however, there is no data on Brazilian reality in this period. In a continent-sized country and such heterogeneous health services as Brazil, preparing such knowledge becomes more important and challenging. This paper proposed to describe early urothelial carcinoma presentation pattern and treatment in Brazilian population (high-risk non-muscle-invasive and localized muscle-invasive) in several sites spread throughout the national territory. Thus, data will be generated to provide a more appropriate understanding of the current landscape and, consequently, the better design of public policies to face this disease.

Conditions

Timeline

Start date
2023-07-10
Primary completion
2024-04-18
Completion
2024-04-18
First posted
2023-07-14
Last updated
2025-04-11

Locations

5 sites across 1 country: Brazil

Source: ClinicalTrials.gov record NCT05945108. Inclusion in this directory is not an endorsement.